News
Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest SAS, a leader in the development and provision of next-generation sequencing (NGS) testing services for biopharmaceuticals
Silence Therapeutics to Participate in September Investor Conferences
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
ICON plc to Present at the Baird Global Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird Global
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system
Agilent Names Philip Binns to Lead Life Sciences and Applied Markets Group
Agilent Technologies, Inc. (NYSE: A) today announced Philip Binns has been named president of the company’s Life Sciences and Applied Markets Group (LSAG). Binns previously served as vice president
NanoString to Webcast Presentations from Upcoming Healthcare Conferences
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets
IMV Inc. (the “Company” or “IMV”) announces today that it has accepted an offer (the “Offer”) from IMV’s largest secured creditors (the “Secured Lenders”), pursuant to which IMV and its subsidiary
Acadia Healthcare to Participate in 2023 Wells Fargo Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 2023 Wells Fargo Healthcare Conference, September 6 - 8, 2023, in Boston.
In connection
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System With a New Aid Offering in Germany
DexCom, Inc. (Nasdaq: DXCM), global manufacturer of systems for real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose
EQS-News: M1 Kliniken AG: Market leader for beauty medicine in Germany opens up in the 9th foreign market and prepares market entry in the USA
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: M1 Kliniken AG publishes figures for the first half year 2023:
EQS-News: Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic